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Background and objectives: African-American (AA) children with focal segmental 
glomerulosclerosis (FSGS) have later onset disease that progresses more rapidly than in 
non-AA children. It is unclear how APOL1 genotypes contribute to kidney disease risk, 
progression, and cardiovascular morbidity in children.
Design, setting, participants, and measurements: We examined the prevalence of 
APOL1 genotypes and associated cardiovascular phenotypes among children with FSGS 
in the Chronic Kidney Disease in Children (CKiD) study; an ongoing multicenter prospec-
tive cohort study of children aged 1–16 years with mild to moderate kidney disease.
results: A total of 140 AA children in the CKiD study were genotyped. High risk (HR) 
APOL1 genotypes were present in 24% of AA children (33/140) and were associated 
with FSGS, p < 0.001. FSGS was the most common cause of glomerular disease in 
children with HR APOL1 (89%; 25/28). Of 32 AA children with FSGS, 25 (78%) had HR 
APOL1. Compared to children with low risk APOL1 and FSGS (comprising 36 non-AA 
and 7 AA), children with HR APOL1 developed FSGS at a later age, 12.0 (IQR: 9.5, 
12.5) vs. 5.5 (2.5, 11.5) years, p =  0.004, had a higher prevalence of uncontrolled 
hypertension (52 vs. 33%, p =  0.13), left ventricular hypertrophy (LVH) (53 vs. 12%, 
p < 0.01), C-reactive protein > 3 mg/l (33 vs. 15%, p = 0.12), and obesity (48 vs. 19%, 
p = 0.01). There were no differences in glomerular filtration rate, hemoglobin, iPTH, or 
calcium–phosphate product.
conclusion: AA children with HR APOL1 genotype and FSGS have increase prevalence 
of obesity and LVH despite a later age of FSGS onset, while adjusting for socioeconomic 
status. Treatment of obesity may be an important component of chronic kidney disease 
and LVH management in this population.
Keywords: cardiovascular, left ventricular hypertrophy, chronic renal disease, Fsgs, children
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inTrODUcTiOn
African-Americans (AA) have higher rates of hypertension 
(HTN) and kidney disease compared to Americans of European 
descent (1). In adults of African descent, the presence of high 
risk (HR) APOL1 genotype (characterized by the presence of two 
risk alleles, defined as G1/G1 homozygotes, G2/G2 homozygotes, 
and G1/G2 compound heterozygotes), preferentially selected by 
the process of evolution, was found to be associated with non-
diabetic or “hypertension-attributed” end-stage renal disease 
(ESRD), idiopathic focal segmental glomerulosclerosis (FSGS), 
and HIV-associated nephropathy (2–5). The role of APOL1 in the 
adult cardiovascular phenotype is still controversial with some 
recent findings, suggesting that APOL1 variants could contrib-
ute to atherosclerotic cardiovascular risk, indicating a genetic 
component to cardiovascular health disparities among adults 
of African ancestry (6). While studies in adult AA populations 
demonstrated strong recessive association of APOL1 G1 and G2 
genetic variants with glomerular and vascular disease progres-
sion (7), there is limited information on its role in children with 
chronic kidney disease (CKD), particularly for cardiovascular 
comorbidities. In NIH FSGS cohort study and in the FSGS-
Clinical Trial (FSGS-CT), both of which included children and 
adults, HR APOL1 genotype was present in 72% of self-identified 
AA subjects (8).
Up to 63% of children with early stages of CKD present 
with arterial HTN (9). In addition to being common, HTN is 
associated with a greater rate of decline in kidney function and 
is a known risk of development of ESRD (10). Furthermore, 
in Chronic Kidney Disease in Children (CKiD), a population 
with mild to moderate CKD, a high overall prevalence (53%) of 
systolic HTN was observed (11). Presence of HTN in children 
with CKD has also been associated with cardiovascular morbid-
ity and development of left ventricular hypertrophy (LVH) (12). 
LVH is common among hypertensive adults and children with 
CKD and is more common among AA than in whites (13, 14). 
While a previous report of two pediatric cohorts representing 
children with CKD (CKiD) and nephrotic syndrome (Nephrotic 
Syndrome Study Network; NEPTUNE) showed similar APOL1 
characteristics in terms of FSGS diagnosis and disease pro-
gression (15), the association of APOL1 and cardiovascular 
comorbidities in the presence of CKD has not been explored. 
The purpose of this study was to extend previous findings (15), 
to characterize the distribution of APOL1 risk alleles in the 
CKiD cohort and, by comparing children with an underlying 
FSGS cause of CKD, to describe the prevalence of cardiorenal 
phenotypes and markers of disease severity associated with the 
HR APOL1 genotype.
MaTerials anD MeThODs
subjects
The study population comprised of children enrolled in the 
CKiD Study, an ongoing multicenter prospective cohort study 
of children aged 1–16  years with mild to moderate kidney 
disease (16).
clinical and laboratory Testing
All clinical and laboratory data in the analysis were based on the 
first available observation, either at study entry or 6 months after, 
and were categorized by indicators of renal, cardiovascular, and 
metabolic health. Echocardiography data were collected 1  year 
after study entry according to study protocol. Race, sociodemo-
graphic, and therapy use were self or parental reported.
Genetic Testing
DNA was obtained from National Institute of Diabetes and 
Digestive and Kidney Disease (NIDDK) genetics repository of 
immortalized lymphocyte cell lines based on a sample of whole 
blood taken at the 6-month-old study visit among those who 
consented to genetic testing. APOL1 variants G1 (rs73885319, 
S342G and rs60945101, I384M) and G2 (rs71785313, NY dele-
tion) were genotyped.
The number of kidney risk alleles defined APOL1 risk 
groups: low risk (LR) was defined by 0 or 1 risk allele (G0/G0 
homozygous, or G1/G0 and G2/G0 heterozygous), and HR was 
defined by 2 risk alleles (G1/G1 and G2/G2 homozygous, or G1/
G2 compound heterozygous), where G0 represents the ancestral 
alleles at both rs73885319 and rs71785313 sites.
Indicators of renal health included glomerular filtration rate 
(GFR) measured by plasma disappearance of iohexol or estimated 
by CKiD-developed equations based on serum creatinine, cysta-
tin C, and BUN, when iohexol GFR was not available. Proteinuria 
was assessed as first morning urine protein (milligrams)/creati-
nine (milligrams) ratio (uPCR).
Indicators of cardiovascular health included the average of 
three in-clinic measurements of blood pressure and left ventricu-
lar mass index (LVMI in g/m2.7) as measured by echocardiogra-
phy. Uncontrolled HTN was defined as systolic blood pressure 
(SBP) or diastolic blood pressure (DBP) ≥95th percentile for age, 
sex, height according to the fourth report (17). LVH was defined 
as LVMI ≥  age- and sex-specific 95th percentile based on the 
normal population (18). All data were measured and defined by 
the CKiD study protocol, as described previously (11, 16, 19).
Indicators of metabolic health included total, HDL, and LDL 
cholesterol (milligrams per deciliter), triglycerides (milligrams 
per deciliter) with age- and sex-defined categorical definitions 
for abnormally high total cholesterol, low HDL, and high LDL 
cholesterol, based on the normal population. Hemoglobin (grams 
per deciliter), calcium (milligrams per deciliter), phosphate (mil-
ligrams per deciliter), and calcium ×  phosphate product were 
measured. Hemoglobin was categorized by anemia status based 
on age- and sex-defined levels of the normal population, and 
phosphate levels were categorized as high based on age-defined 
levels of the normal population. Intact parathyroid hormone 
(iPTH) and C-reactive protein (CRP) were also measured (19), 
with high sensitivity CRP primarily used (n =  47) and when 
missing, informed by wide-range CRP data (n = 18; missing both 
n = 3). High CRP was defined as CRP > 3 mg/l.
The CKiD Study protocol was approved by the institutional 
review boards at the participating institutions, and all subjects 
gave informed assent or consent. Genetic testing was approved 
by the NIDDK Institutional Review Board.
FigUre 1 | Distribution of cKiD children by race [african-american (aa) vs. non-african-american (non-aa)], APOL1 genotypes, and cKD diagnoses 
[glomerular disease (glom), non-glomerular disease (non-glom), focal segmental glomerulosclerosis (Fsgs)] all genotyped non-aa (N = 37) were 
found to have lr APOL1 status, providing a justification for classifying non-aa children as low risk.
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statistical analyses
Since 89% of children with the HR APOL1 profile had FSGS, the 
appropriate comparison group to determine differences related 
to APOL1 were children with LR APOL1 genotype and FSGS. 
Fisher’s exact test for categorical variables and the Wilcoxon 
rank-sum test for continuous variables were used to compare 
univariate differences by APOL1 risk status among those with a 
diagnosis of FSGS.
Since lower socioeconomic status (SES) was associated with 
AA race in this North American cohort, and low SES is associated 
with disease progression (20), SES is a potential confounder as the 
exposure groups largely differ by race. To adjust for confound-
ing due to SES, we used inverse probability of exposure weights 
(IPWs) (21, 22). The IPWs were generated from a logistic regres-
sion model with HR APOL1 as the outcome and variables related 
to SES as the predictors: income less than $36,000, maternal 
education less than college, the presence of any public insur-
ance and missing at least one dose of antihypertensive therapy 
in the past 7  days (self-reported). The inverse of the predicted 
probability of observed exposure was stabilized to the marginal 
probability of each group (for HR APOL1: 25/68 = 0.37; and for 
LR APOL1: 43/68 =  0.63). Selected cardiovascular, metabolic, 
inflammatory, and other risk factors were compared to exposure 
group in adjusted analyses using weighting by IPWs in logistic 
regression models to obtain prevalence odds ratio comparing the 
HR APOL1 group to the LR APOL1 group. The outcomes were 
obesity, high LDL cholesterol, uncontrolled HTN, LVH, and 
CRP > 3 mg/l. Multiple imputation was used to account for miss-
ing data, and the results are presented unadjusted (univariately, 
with imputation where applicable) and adjusted to account for 
the effect of confounding by SES.
resUlTs
A total of 891 children were enrolled in CKiD, of whom 199 (22%) 
were AA; Figure 1 presents the distributions of APOL1 genotypes 
and CKD diagnoses by race. Among 140 genotyped AA children, 
HR APOL1 status was present in 33 (24%), and among these 
33 individuals 28 (85%) had an underlying glomerular cause of 
CKD, whereas only 5/33 (6%) had a non-glomerular cause of 
CKD, p < 0.001. Of those 28 subjects with HR APOL1 status and 
a glomerular disease, 25/28 (89%) had a diagnosis of FSGS. In 
contrast, among 191 non-AA children with a glomerular CKD 
cause, only 36 (19%) had an FSGS diagnosis, p < 0.001. Of the 
28 AA children with LR APOL1 status (defined as presence of 0 
or 1 risk allele), and glomerular CKD, 7 (25%) had a diagnosis 
of FSGS (difference between HR and LR APOL1 AA, p < 0.001). 
APOL1 genotyping was not performed in 59 children: 20 did not 
consent to genetic testing, 19 dropped out of the study prior to 
sample collections, 9 were not measured due to missing samples, 
and 11 samples became available only after genotyping had been 
completed. Of these 59 children, 47% had a glomerular cause of 
CKD; 39% of these had a diagnosis of FSGS. The similar propor-
tions of glomerular diagnoses and FSGS among AA LR APOL1 
and non-AA LR APOL1 children (i.e., 25 and 19%, respectively) 
suggest potentially similar pathologic mechanisms and were 
distinct from the distributions observed among AA children with 
HR APOL1. The proportion (47%) of FSGS diagnoses among 
children with unmeasured APOL1 status is intermediate between 
that observed among those with HR (85%) and LR (25%), sug-
gesting that this group with unmeasured genotypes comprises 
both HR and LR profiles. A total of 37 non-AA children were 
genotyped, and all were identified as having LR APOL1 status 
TaBle 1 | Descriptive statistics of sociodemographic, renal health, and therapy use among children with Fsgs, by race and APOL1 risk status  
(lr, low risk vs. hr, high risk; non-aa, non-african-american; aa, african-american), in the cKiD study (n = 68), median (iQr), n (%); p-values based on 
Fisher’s exact test or Wilcoxon rank-sum test.
Variable non-aa APOL1 lr 
n = 36
aa APOL1 lr  
n = 7
Pooled APOL1 lr 
n = 43
APOL1 hr  
n = 25
p-Value  
(pooled lr vs. hr)
Male 21 (58%) 4 (57%) 25 (58%) 11 (44%) 0.318
Black race 0 7 (100%) 7 (16%) 25 (100%) NA
Age at study entry, years 13.8 [9.6, 15.6] 15.0 [8.2, 16.5] 14.2 [9.5, 15.8] 14.8 [13.0, 15.5] 0.312
Low birth weight (<2500 g) 7 (21%) 1 (17%) 8 (21%) 8 (33%) 0.372
Premature 2 (6%) 0 (0%) 2 (5%) 7 (29%) 0.011
Small for gestational age 7 (23%) 2 (33%) 9 (24%) 7 (30%) 0.765
Low birth weight, premature, or 
small for gestational age
10 (29%) 2 (29%) 12 (29%) 13 (52%) 0.070
Height, cm 147 [135, 163] 147 [128, 160] 147 [135, 163] 164 [149, 171] 0.003
Height percentile 24 [4, 59] 14 [1, 47] 23 [3, 55] 40 [27, 86] 0.033
Weight, kg 46.4 [34.4, 56.5] 47.1 [27.4, 72.4] 46.4 [34.0, 57.3] 73.5 [60.4, 90.6] <0.001
Weight percentile 53 [20, 77] 59 [14, 91] 54 [18, 77] 97 [71, 99] <0.001
Body mass index, kg/m2 20.2 [17, 23.9] 19.4 [16.6, 27.1] 20 [17.4, 24.1] 25.1 [22.9, 36.3] <0.001
BMI percentile 74 [28, 93] 77 [38, 91] 76 [33, 93] 93 [82, 99] <0.001
Obese 7 (19%) 1 (14%) 8 (19%) 12 (48%) 0.014
socioeconomic variables
Household income
<$36,000 15 (43%) 2 (33%) 17 (41%) 12 (48%) 0.409
≥$36,000 and <$75,000 11 (31%) 2 (33%) 13 (32%) 10 (40%)
≥$75,000 9 (26%) 2 (33%) 11 (27%) 3 (12%)
Maternal education < college 26 (74%) 6 (86%) 32 (76%) 17 (68%) 0.571
Any public insurance 19 (53%) 2 (29%) 21 (49%) 15 (60%) 0.453
renal health
Age at CKD onset, years 6.5 [2.5, 11.5] 4.5 [3.5, 3.5] 5.5 [2.5, 11.5] 12.0 [9.5, 12.5] 0.004
Years with CKD 5.3 [3.4, 7.9] 3.7 [2.2, 2.3] 5.2 [3.3, 7.9] 3.3 [1.1, 4.7] 0.008
ieGFR at entry, ml/min/1.73 m2 48 [34, 71] 32 [26, 98] 48 [32, 79] 61 [48, 69] 0.132
IeGFR < 45 ml/min/1.73 m2 14 (39%) 4 (57%) 18 (42%) 6 (24%) 0.190
ieGFR change per year, % −7.4% [−3.1%, −2.9%] −2.2% [−14.0%, −14.2%] −7.4% [−23.0%, −2.9%] −8.3% [−14.9%, −1.7%] 0.994
ieGFR change per year, ml/min −4.1 [−12.3, −1.7] −2.5 [−7.8, 5.9] −4.8 [−12.8, −1.7] −4.4 [−9.6, −1.1] 0.903
uPCR at entry, mg/mg creatinine 1.6 [0.2, 5.5] 1.0 [0.1, 1.2] 1.5 [0.2, 5.5] 0.9 [0.3, 1.8] 0.330
Proteinuria, uPCR > 2 15 (43%) 3 (43%) 18 (43%) 3 (13%) 0.025
Therapy use
Anti-hypertension therapy 31 (86%) 7 (100%) 38 (88%) 25 (100%) 0.150
ACEi/ARB therapy 29 (81%) 7 (100%) 36 (84%) 22 (88%) 0.735
Missed ACEi/ARB in last 30 days 7 (19%) 1 (14%) 8 (19%) 4 (16%) 1.000
Missed ACEi/ARB in last 7 days 6 (17%) 3 (43%) 9 (21%) 10 (40%) 0.103
Steroid therapy 7 (19%) 2 (29%) 9 (21%) 8 (32%) 0.387
Immunosuppression therapy 17 (47%) 5 (71%) 22 (51%) 14 (56%) 0.803
BMI, body mass index; CKD, chronic kidney disease; ieGFR, measured or estimated glomerular filtration rate; uPCR, urine protein to creatinine ratio.
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(36 had 0 risk alleles and 1 harbored 1 risk allele). This provided 
justification for classifying non-AA children as LR. A full list of 
diagnoses by race and APOL1 status is provided in Table S1 in 
Supplementary Material.
We compared the prevalence of renal and cardiovascular risk 
factors by APOL1 status and AA race within FSGS diagnosis group 
(n = 68). Since there were only seven subjects with LR APOL1 and 
AA race, we pooled both AA (n = 7) and non-AA (n = 36) chil-
dren as the reference population for statistical comparison with 
AA children with HR APOL1 and FSGS (n = 25). Table 1 presents 
the clinical, sociodemographic, and renal characteristics among 
those with FSGS, stratified by race and APOL1 risk status. There 
were similar proportions of boys and despite similar ages at study 
entry, those with HR APOL1 were significantly taller (p = 0.003) 
and heavier (p < 0.001), compared to children with LR APOL1. 
This was reflected in the height and weight percentiles standard-
ized to age and gender (i.e., normal, median height, and weight 
percentiles are equal to 50): those with HR APOL1 had a median 
height and weight percentiles significantly higher as compared 
to those with LR APOL1, p = 0.033 and p < 0.001, respectively. 
Body mass index (BMI) was significantly higher among the HR 
APOL1 children (p < 0.001), and this group had a much higher 
proportion of obesity (BMI >  85th percentile adjusted for age 
and gender; 48 vs. 19%, p =  0.01). Consistent with previously 
published reports (15), children with HR APOL1 had a higher 
prevalence of premature birth than children with LR APOL1 (29 
vs. 5%, p = 0.011), but this difference was not observed for low 
birth weight or small for gestational age.
To account for the potential confounding effects of SES factors 
related to race, inverse probability weights were used to adjust 
raeyrep
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FigUre 2 | Percentile boxplots of longitudinal gFr changes based on individual regression equations, expressed as percent change per year, by 
APOL1 risk and race. A total of six non-AA LR participants, two AA LR participants, and two AA HR participants only contributed one GFR measurement and 
were not included in this analysis.
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for sex, income, maternal education, insurance status, and 7-day 
adherence to antihypertensive therapy. We found no statistical 
differences in SES variables between HR and LR APOL1 genotype 
groups.
In this comparison, those children with FSGS and HR APOL1 
had a significantly older age at CKD onset, and significantly 
shorter duration of CKD than those with LR APOL1. Children 
with HR APOL1 had a higher GFR at entry although this dif-
ference was not statistically significant, p =  0.132. Changes in 
GFR over time were similar to APOL1 status (Figure 2). Levels 
of uPCR at entry and over time were also similar, although the 
HR APOL1 group had a lower proportion with nephrotic range 
proteinuria at study entry, p = 0.025.
Table 2 and Table S2A,B in Supplementary Material describe 
characteristics related to cardiovascular health stratified by race 
and APOL1 risk status among those with an FSGS cause of CKD. 
Children with HR APOL1 had higher SBP (p = 0.004), although 
SBP percentiles (standardized to the normal population for age, 
gender, and height) were not statistically significant (p = 0.132). 
No significant differences in DBP were observed. The HR APOL1 
children had a higher prevalence of uncontrolled HTN, although 
it was not statistically significant. Nearly all children, regardless of 
APOL1 status received antihypertensive therapy, the HR APOL1 
group had higher (40 vs. 21%) 7-day non-adherence to ACEi/
ARB therapy, p = 0.103 (Table 1). The proportions receiving glu-
cocorticoid and other immunosuppression therapy were similar 
by APOL1 risk status.
Increased left ventricular mass index (p = 0.004) and a higher 
prevalence of LVH (p = 0.003) were observed in the HR APOL1 
group. LDL cholesterol was higher in the HR APOL1 group 
(p = 0.047), but no differences in total cholesterol, HDL choles-
terol, and triglyceride levels were observed. Higher phosphate 
was observed among the LR APOL1 group (p = 0.023), but there 
was no difference in intact parathyroid hormone. Children with 
HR APOL1 had a higher proportion of CRP values greater than 
3 mg/l (33 vs. 15%, p = 0.120).
Table 3 presents odds ratios to describe the associations of 
the HR APOL1 profile and selected risk factors and comor-
bidities. LVH was highly associated with HR APOL1 (OR: 6.2, 
95%CI: 1.6, 24.9), as was obesity (OR: 4.7, 95%CI: 1.5, 14.4). 
While not statistically significant, HR APOL1 had a higher rela-
tive odds of uncontrolled HTN, elevated CRP, and high LDL 
cholesterol.
DiscUssiOn
In this cohort of children with FSGS, we demonstrated that AA 
children with HR APOL1 genotype were more likely to have FSGS 
and to have a later age at FSGS onset, compared to AA children 
with LR genotypes. When restricting analysis to children with 
FSGS, HR APOL1 was associated with a greater cardiovascular 
risk burden, including an increase prevalence of LVH, and obe-
sity, a higher LVMI, BMI, and LDL cholesterol, despite treatment 
with antihypertensive therapy and adjustment for indicators of 
SES. Notably, other markers of disease severity were not different 
between the two groups indicating a potential role for APOL1 in 
the etiology of cardiovascular abnormalities.
TaBle 3 | relative odds of selected risk factors and comorbidities 
comparing aa children with Fsgs and hr APOL1 to pooled children (i.e., 
non-aa and aa) with Fsgs and lr APOL1 based on logistic regression 
models.
Unadjusted odds ratios 
(95%ci)
adjusted odds ratios 
(95%ci)
Left ventricular hypertrophy 7.97 (1.90, 33.51) 6.22 (1.55, 24.91)
Obesity 4.04 (1.35, 12.11) 4.65 (1.50, 14.43)
Uncontrolled hypertension 2.24 (0.82, 6.17) 2.54 (0.92, 7.00)
C-reactive protein > 3 mg/l 2.74 (0.82, 9.16) 2.41 (0.67, 8.72)
High LDL cholesterol 1.34 (0.44, 4.08) 1.22 (0.40, 3.72)
Analyses are unadjusted and adjusted for sex, income less than $30,000, maternal 
education less than college, household having any public insurance, and missing a 
dose of antihypertensive medication in the past 7 days, as markers of socioeconomic 
status. Multiple imputation was used to account for missing data.
LDL, low density lipoprotein.
TaBle 2 | cardiovascular and metabolic characteristics among children with Fsgs, by race and APOL1 status.
Variable non-aa APOL1 lr  
n = 36
aa APOL1 lr  
n = 7
Pooled APOL1 lr  
n = 43
APOL1 hr  
n = 25
p-Value  
(pooled lr vs. hr)
SBP, mmHg 108 [103, 117] 114 [109, 124] 109 [103, 119] 120 [113, 127] 0.004
SBP percentile 62 [43, 81] 88 [48, 97] 64 [45, 88] 79 [55, 95] 0.132
DBP, mmHg 66 [61, 77] 73 [67, 88] 69 [61, 79] 67 [63, 75] 0.889
DBP percentile 64 [36, 88] 90 [58, 99] 68 [37, 92] 57 [46, 85] 0.377
Uncontrolled hypertension 10 (28%) 4 (57%) 14 (33%) 13 (52%) 0.131
LVMI at V2, g/m2.7 30.0 [26.9, 33.0] 28.1 [20.7, 28.6] 29.6 [26.9, 33.0] 40.8 [28.1, 52.9] 0.004
LVH at V2 4 (13.8%) 0 (0%) 4 (12%) 9 (45%) 0.003
Total cholesterol, mg/dl 173 [150, 210] 186 [174, 205] 174 [150, 210] 190 [168, 224] 0.222
High total cholesterol 10 (33%) 2 (40%) 12 (34%) 9 (43%) 0.565
HDL cholesterol, mg/dl 53 [41, 61] 53 [50, 66] 53 [41, 63] 51 [41, 60] 0.883
Low HDL cholesterol 4 (13%) 0 (0%) 4 (11%) 0 (0%) 0.286
LDL cholesterol, mg/dl 90 [71, 120] 98 [97, 123] 92 [71, 122] 112 [101, 145] 0.047
High LDL cholesterol 5 (17%) 1 (20%) 6 (17%) 7 (33%) 0.208
Triglycerides, mg/dl 143 [92, 203] 118 [93, 160] 136 [92, 200] 117 [91, 145] 0.441
High triglycerides 18 (60%) 3 (60%) 21 (60%) 10 (48%) 0.578
Hemoglobin, g/dl 12.5 [11.3, 13.4] 11.7 [10.0, 12.9] 12.3 [11.1, 13.3] 12.4 [11.9, 13.6] 0.165
Anemia 17 (47%) 5 (71%) 22 (51%) 8 (32%) 0.139
Calcium, mg/dl 9.2 [8.5, 9.6] 9.6 [8.0, 9.8] 9.2 [8.4, 9.6] 9.4 [9.1, 9.7] 0.179
Phosphate (mg/dl) 4.5 [4.0, 5.1] 4.1 [3.7, 6.0] 4.4 [4.0, 5.1] 4.3 [3.7, 4.7] 0.154
High phosphate 6 (17%) 2 (29%) 8 (19%) 0 (0%) 0.023
Calcium × phosphate 41.7 [37.4, 44.8] 41.0 [36.3, 48.0] 41.4 [37.0, 45.0] 39.9 [34.0, 45.6] 0.504
iPTH, pg/ml 58.0 [35.8, 89.8] 144.3 [40.0, 267.8] 58.0 [38.0, 95.0] 52.0 [39.5, 67.0] 0.399
CRP > 3 mg/l 4 (12%) 2 (29%) 6 (15%) 8 (33%) 0.120
Median [IQR] or (CI), n (%); p-values based on Fisher’s exact test or Wilcoxon rank-sum test.
SBP, systolic blood pressure; DBP, diastolic blood pressure; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; V2, visit at 12 months post study enrollment; HDL, 
high density lipoprotein; LDL, low density lipoprotein; iPTH, intact parathyroid hormone; CRP, C-reactive protein (high sensitivity or wide range).
Uncontrolled hypertension was defined as SBP or DBP ≥ 95th percentile for age, sex, and height, regardless of a self-reported history of hypertension or receiving antihypertensive 
therapy.
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In children with biopsy confirmed FSGS enrolled in the 
FSGS-CT, 72% of self-identified AA subjects and 6% of children 
who identified themselves as non-AA had HR APOL1 risk alleles 
(8). In the CKiD population, HR APOL1 risk genotype was strongly 
associated with both glomerular disease and FSGS. Strikingly, the 
prevalence of HR APOL1 among AA children with FSGS was 76% 
(25/33), and this was congruent with the 72% observed in the 
FSGS-CT. The distribution of APOL1 genotypes observed in the 
adult normal population did not differ from Hardy–Weinberg 
expectations for genotype distribution; there was no loss of one 
particular genotype group or gain in another. This provides 
population-based statistical evidence that there is no preferential 
loss of HR genotypes between conception and adulthood (2–5). 
While our study focused on children who have already been 
diagnosed with CKD, we are unable to make inferences about the 
general (i.e., non-diseased) pediatric population. Future studies 
may wish to characterize the distribution of APOL1 risk alleles in 
this group to better understand population risk in children.
Previous studies have established that APOL1 kidney risk 
variants are strongly associated with kidney disease among adult 
AA; specifically, HIV-associated nephropathy (odds ratio, 29; 
95% confidence interval, 13–68) and FSGS (odds ratio, 17; 95% 
confidence interval, 11–26) (2–5). In the CKiD cohort, the HR 
APOL1 genotype was associated with the glomerular phenotype 
in children younger than previously reported; previous studies 
have established that APOL1-associated FSGS is characterized by 
a tendency to present between ages 15 and 39 years old (7) and in 
FSGS-CT with median age 17 years (13, 23) (8). The median age 
of FSGS onset among HR children was 12 years in CKiD, which 
was older than other LR children with FSGS, a finding previously 
reported alongside the NEPTUNE children with nephrotic syn-
drome (15). Additionally, this study found a higher prevalence of 
prematurity among those with HR APOL1 compared to AA and 
non-AA children with FSGS, similar to findings with NEPTUNE 
that employed a different reference group, suggesting that the 
prematurity effect extends to non-AA children.
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It has been well established that AA children with FSGS 
have later onset disease than non-AA children and progress 
more rapidly to ESRD (23, 24). In addition, AA children with 
nephrotic syndrome have a seven times greater risk of having 
been diagnosed with FSGS than Hispanics (Mexicans and other 
immigrants from Central America, but not Puerto Ricans and 
other Caribbean immigrants) (23), and this has been attributed 
to genetic factors. The present analysis suggest that among chil-
dren with CKD, AA children with HR APOL1 genotype present 
with later onset kidney disease, and have a higher prevalence of 
cardiovascular and metabolic comorbidities than patients with 
LR APOL1 genotype, despite a shorter duration of disease and 
the same diagnosis of FSGS. This would suggest that in children 
with HR genotypes, FSGS might have a different pathophysiol-
ogy with the added influence of distinctive environmental factors 
(i.e., obesity and potentially birth history, toxin exposure, and/or 
additional genetic factors). This in turn may lead to a “vascular/
endothelial” phenotype clinically presenting as uncontrollable 
HTN and LVH leading to “enhanced” podocyte injury; in con-
trast, non-AA primary FSGS may be characterized by a “primary 
podocyte” phenotype, earlier onset, and slower CKD progres-
sion. It is unclear at present how G1 and G2 alleles may cause 
endothelial or podocyte damage, although the APOL1 protein 
forms pores in the lysosomal membrane, leading to pathogen 
lysis, and a variant APOL1 protein was shown in transgenic mice 
to induce direct tissue injury (25).
The role of APOL1 in the adult cardiovascular phenotype 
remains controversial. Ito et al. (6) using data from the Jackson 
Heart Study (JHS) and Women’s Health Initiative (WHI) demon-
strated that the APOL1 kidney risk alleles confer a twofold risk 
of cardiovascular events, without significant changes in left ven-
tricular mass, whereas the Systolic Blood Pressure Intervention 
Trial (SPRINT) showed the absence of an APOL1 association with 
prevalent cardiovascular disease in a non-diabetic adult sample 
(26). It is possible that cardiovascular disease–APOL1 interaction 
may have an age-dependent relationship pattern, similar to one 
described in early- and late-onset forms of Alzheimer disease 
associated with apolipoprotein E, epsilon 4 allele, where subjects 
at both age spectrum (young-old) seem to be affected by the 
disease penetrance (27). It is unknown if similar age-dependent 
relationship pattern could also be seen in cardiovascular disease–
APOL1 interaction.
Furth et al. (19) described cardiovascular disease risk factors 
in the CKiD cohort and found that only 18% of the cohort exhib-
ited CRP values >3  mg/l (independent of GFR). In our study, 
elevated CRP was not statistically different between HR and LR 
APOL1 children with FSGS, suggesting that inflammation is not 
a driving factor behind LVH. It is possible that differences in LVH 
are driven by a combination of APOL1 genotype, underlying 
metabolic status, obesity/BMI, HTN, and some other unrecog-
nized socioeconomic or racial variables. Our results showed an 
excess of obesity among those with HR APOL1. Since obesity and 
metabolic dysregulation are risk factors for both cardiovascular 
disease and CKD onset and progression, managing weight prior 
to onset in order to prevent or delay disease may be an impor-
tant clinical consideration. Future studies should seek to clarify 
whether the effect of APOL1 on CKD severity is related to obesity 
or whether these two outcomes are independently influenced 
by the HR profile. Our finding of increased cardiovascular and 
metabolic risks associated with HR genotype in children with 
CKD underscores the importance of early detection and need 
for more aggressive treatment of obesity, such as early therapy or 
adherence support, in this population.
It is also possible that the increased cardiovascular risk in the 
HR children is a consequence of the underlying glomerular dis-
ease (FSGS) severity and rate of progression. HTN-misattributed 
kidney disease in AA has been described in the adult literature 
(28). Given the cross-sectional nature of this study, future 
research efforts might investigate a large group of AA children 
with non-glomerular/congenital kidney disease to investigate 
the effect of HR APOL1 on cardiovascular risk, in the absence of 
podocyte injury and glomerular damage. Since the vast majority 
of HR children in CKiD had a glomerular disease (85%), we were 
unable to assess the effect of APOL1 HR on cardiovascular risk 
among those with a non-glomerular condition.
This study has several limitations. First, the LR APOL1 
subgroup with FSGS was predominantly non-AA. There were 
only 7 AA with LR APOL1 compared to 25 AA children with 
HR APOL1 and FSGS, thus highlighting the strong association 
between HR APOL1 and FSGS among AA children. Since other 
forms of glomerular disease among the AA LR APOL1 children, 
such as hemolytic uremic syndrome, familial nephritis, or SLE, 
were less common than FSGS in AA HR group, we chose to 
restrict our analysis to only those with FSGS to determine the 
effect of HR APOL1 among those with the same CKD pathology, 
which necessitated inclusion of non-AA children with FSGS. 
Although a minority of non-AA subjects were genotyped; all 
had LR APOL1 status, providing a justification for classifying 
non-AA children as LR. It is possible that some children were 
misclassified, particularly those of Hispanic ethnicity, although 
this misclassification would lead to more conservative estimates. 
Ideally, our study would have included a large group of LR and HR 
APOL1 AA children with FSGS. As such, we cannot completely 
discount genetic (non-APOL1) or metabolic factors related to 
race explaining these effects. A related limitation is the potential 
confounding effect of race and SES, given the disparate distribu-
tions of race between the exposed and unexposed groups. While 
several key SES variables were not associated with our exposure, 
7-day antihypertensive adherence was related to HR APOL1. 
Inverse probability or exposure weights were used to account 
for potential differences in SES variables in adjusted analyses, 
but there may be other unmeasured SES variables possibly con-
founding these relationships. The third limitation was the lack 
of DNA for analysis in 59 subjects (28 subjects with glomerular 
disease), reducing statistical power. We did not characterize 
ancestry-informative markers, and therefore, we did not deter-
mine the fraction of African ancestry among subjects, although 
this information would likely not change any inferences, since 
the prevalence of HR APOL1 genotype in this study was nearly 
identical to that previously reported (5, 7, 8). Finally, this study 
was limited in sample size and may be considered preliminary 
data for future research to build upon. These findings need to 
be replicated in larger populations in both children and adults. 
Despite these limitations, the association of HR APOL1 genotype 
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with development of glomerular disease, later onset of FSGS and 
indications of increased cardiovascular risk among children were 
compelling.
In conclusion, this study suggests that APOL1-associated risks 
are not restricted to adults only and are present in young children 
as well. Indeed, in CKiD, cardiovascular abnormalities were more 
common among AA children with HR APOL1. Targeting these 
established modifiable comorbidities, especially BMI, obesity, 
and HTN, may be a particularly important component in CKD 
management to delay ESRD in this HR population.
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